Cholesterol Metabolism in Active Crohn's Disease

Overview

Journal Wien Klin Wochenschr

Publisher Springer

Specialty General Medicine

Date 2009 Jun 30

PMID 19562284

Citations 19

Authors

Vladimir Hrabovsky

Zdenek Zadak

Vladimir Blaha

Radomir Hyspler

Tomas Karlik

Arnost Martinek

Alice Mendlova

Affiliations

Soon will be listed here.

Abstract

Hypocholesterolemia has been investigated as a typical feature of critical illness and is connected with poor prognosis. Crohn's disease is an inflammatory process and is associated with several metabolic disturbances. In recent decades clinical studies have established a link between lipid metabolism and systemic inflammation. In our study we examined the serum profile of cholesterol (total cholesterol, LDL- and HDL-cholesterol) and changes in the cholesterol absorption/synthesis process by determination of plasma non-cholesterol sterol (squalene, lathosterol, campesterol, sitosterol) concentrations. Serum concentrations of total cholesterol, LDL- and HDL-cholesterol and non-cholesterol sterols were evaluated in 24 patients with active Crohn's disease during a period of 28 days. We detected lower serum levels of total cholesterol (P < 0.001), LDL- and HDL-cholesterol (P < 0.05) in the patients with active Crohn's disease than in the control group. In addition, the patients had significantly lower plasma levels of lathosterol (P < 0.001) and higher concentrations of squalene, although without significant differences. A significant decrease of campesterol plasma levels (P < 0.001) was detected, but lower plasma concentrations of sitosterol were without statistical significance. The active phase of Crohn's disease is characterized by altered metabolism of lipids, mainly of cholesterol. Our results show abnormalities in plasma concentrations of non-cholesterol sterols and provide evidence that the process of cholesterol synthesis and absorption is altered in active Crohn's disease.

Citing Articles

Differential analysis of sorting nexin 10 and sterol regulatory element-binding protein 2 expression in inflammatory bowel disease.

Xie B, Zhang A, Li C, Liu Y, Deng Y, Li R Immunol Res. 2024; 72(6):1417-1423.

PMID: 39412576 DOI: 10.1007/s12026-024-09539-9.

Explainable AI-prioritized plasma and fecal metabolites in inflammatory bowel disease and their dietary associations.

Onwuka S, Bravo-Merodio L, Gkoutos G, Acharjee A iScience. 2024; 27(7):110298.

PMID: 39040076 PMC: 11261406. DOI: 10.1016/j.isci.2024.110298.

Gut ribotoxic stress responses facilitate dyslipidemia via metabolic reprogramming: an environmental health prediction.

Kim J, Jeong H, Ray N, Kim K, Moon Y Theranostics. 2024; 14(3):1289-1311.

PMID: 38323314 PMC: 10845207. DOI: 10.7150/thno.88586.

Crohn's disease as the intestinal manifestation of pan-lymphatic dysfunction: An exploratory proposal based on basic and clinical data.

Zhou Y, Ren Y, Lu M, Xu L, Cheng W, Zhang M World J Gastroenterol. 2024; 30(1):34-49.

PMID: 38293325 PMC: 10823898. DOI: 10.3748/wjg.v30.i1.34.

Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis.

Chen H, Li W, Hu J, Xu F, Lu Y, Zhu L Front Med (Lausanne). 2023; 10:1198988.

PMID: 37692785 PMC: 10484721. DOI: 10.3389/fmed.2023.1198988.

References

Miura S, Tsuzuki Y, Hokari R, Ishii H . Modulation of intestinal immune system by dietary fat intake: relevance to Crohn's disease. J Gastroenterol Hepatol. 1999; 13(12):1183-90. View

Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M . Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med. 1996; 334(24):1557-60. DOI: 10.1056/NEJM199606133342401. View

McClane S, Rombeau J . Cytokines and inflammatory bowel disease: a review. JPEN J Parenter Enteral Nutr. 1999; 23(5 Suppl):S20-4. DOI: 10.1177/014860719902300506. View

Druml W . Is cholesterol a conditionally essential nutrient in critically ill patients?. Wien Klin Wochenschr. 2004; 115(21-22):740-2. DOI: 10.1007/BF03040497. View

Hudgins L, Parker T, Levine D, Gordon B, Saal S, Jiang X . A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J Lipid Res. 2003; 44(8):1489-98. DOI: 10.1194/jlr.M200440-JLR200. View

Fraunberger P, Nagel D, Walli A, Seidel D . Serum cholesterol and mortality in patients with multiple organ failure. Crit Care Med. 2000; 28(10):3574-5. DOI: 10.1097/00003246-200010000-00047. View

van der Voort P, Gerritsen R, Bakker A, Boerma E, Kuiper M, de Heide L . HDL-cholesterol level and cortisol response to synacthen in critically ill patients. Intensive Care Med. 2003; 29(12):2199-2203. DOI: 10.1007/s00134-003-2021-7. View

Tilvis R, Miettinen T . Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr. 1986; 43(1):92-7. DOI: 10.1093/ajcn/43.1.92. View

Bakalar B, Hyspler R, Pachl J, Zadak Z . Changes in cholesterol and its precursors during the first days after major trauma. Wien Klin Wochenschr. 2004; 115(21-22):775-9. DOI: 10.1007/BF03040502. View

10.

Kuksis A . Plasma non-cholesterol sterols. J Chromatogr A. 2002; 935(1-2):203-36. DOI: 10.1016/s0021-9673(01)01226-2. View

11.

Gordon B, Parker T, Levine D, Saal S, Wang J, SLOAN B . Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med. 2001; 29(8):1563-8. DOI: 10.1097/00003246-200108000-00011. View

12.

Stachon A, Boning A, Weisser H, Laczkovics A, Skipka G, Krieg M . Prognostic significance of low serum cholesterol after cardiothoracic surgery. Clin Chem. 2000; 46(8 Pt 1):1114-20. View

13.

Pfohl M, Naoumova R, Kim K, Thompson G . Use of cholesterol precursors to assess changes in cholesterol synthesis under non-steady-state conditions. Eur J Clin Invest. 1998; 28(6):491-6. DOI: 10.1046/j.1365-2362.1998.00321.x. View

14.

Bamba T, Shimoyama T, Sasaki M, Tsujikawa T, Fukuda Y, Koganei K . Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2003; 15(2):151-7. DOI: 10.1097/00042737-200302000-00008. View

15.

Geerling B, v Houwelingen A, Stockbrugger R, Brummer R . The relation between antioxidant status and alterations in fatty acid profile in patients with Crohn disease and controls. Scand J Gastroenterol. 1999; 34(11):1108-16. DOI: 10.1080/003655299750024913. View

16.

Trebble T, Wootton S, May A, Erlewyn-Lajeunesse M, Chakraborty A, Mullee M . Essential fatty acid status in paediatric Crohn's disease: relationship with disease activity and nutritional status. Aliment Pharmacol Ther. 2003; 18(4):433-42. DOI: 10.1046/j.1365-2036.2003.01707.x. View

17.

Bonville D, Parker T, Levine D, Gordon B, Hydo L, Eachempati S . The relationships of hypocholesterolemia to cytokine concentrations and mortality in critically ill patients with systemic inflammatory response syndrome. Surg Infect (Larchmt). 2004; 5(1):39-49. DOI: 10.1089/109629604773860291. View

18.

Gassull M, Fernandez-Banares F, Cabre E, Papo M, Giaffer M, Richart C . Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut. 2002; 51(2):164-8. PMC: 1773299. DOI: 10.1136/gut.51.2.164. View

19.

Matsui T, Sakurai T, Yao T . Nutritional therapy for Crohn's disease in Japan. J Gastroenterol. 2005; 40 Suppl 16:25-31. DOI: 10.1007/BF02990575. View

20.

Levy E, Rizwan Y, Thibault L, Lepage G, Brunet S, Bouthillier L . Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr. 2000; 71(3):807-15. DOI: 10.1093/ajcn/71.3.807. View